Dr Fintan Walton, CEO, PharmaVentures, says, 'This show, the first in a
monthly series, provides viewers across the pharmaceutical and biotechnology sectors with insightful analysis and debate covering major transactions and industry trends. It gives exclusive access to topical interviews with senior
executives and experts, including views from the corporate finance sector.'
Accessible via the PharmaVentures' website in various media formats, the
television broadcast exploits the fastest growing media channel available.
According to research carried out by Accustream iMedia Research in 2005, video
streams viewed rose by 50.2% in 2005 and are forecast to grow by a further 32%
this year.
In addition to providing lively coverage of news and current affairs in
the industry, and a review of market trends, this first edition of Business
Review features interviews with key players in the financing of Australian
biotech companies, as well as a round-table discussion focusing on Mergers and
Acquisitions in the pharmaceutical and biotechnology sectors. Dr Fintan
Walton leads a discussion with an expert panel involving: Glyn Edwards, CEO, Antisoma; Charles Macfarlane, Executive Director Worldwide Alliances, Licensing and Acquisitions, Procter and Gamble; Ulrich Kinzel, Director, Nomura Code Securities. Issues debated include recent trends and whether M&As actually work.
Dr Fintan Walton explains, 'PharmaVentures Business Review builds on the
suite of intelligence products available through our PharmaDeals brand and is
the first in the next generation of strategic intelligence products. By
utilising the internet channel to distribute a television show, we can provide
a valuable service industry wide at levels previously unattainable, and enable
companies involved to reap the benefits that such high-profile exposure will
bring.'
PharmaVentures is offering corporate sponsorship and advertising
opportunities to those wishing to promote their company through this unique
format.
Source: PTINEWS
Careers
